U.S. authorities opened an investigation into Chinese state support and pricing practices in the biotech sector, flagging potential market manipulation that could disadvantage American firms. BioCentury reported that the International Trade Commission will examine subsidies and pricing behavior, a move that could form the basis for tariffs or trade restrictions if evidence supports undue state backing. The probe amplifies existing trade scrutiny and may affect collaboration, supply chains and outbound investment in biotech. Industry stakeholders warned the inquiry could have far‑reaching consequences for cross‑border partnerships, licensing and manufacturing arrangements.